Pulmonx (NASDAQ:LUNG) Now Covered by Analysts at D. Boral Capital

D. Boral Capital began coverage on shares of Pulmonx (NASDAQ:LUNG) in a research report sent to investors on Monday, MarketBeat reports. The brokerage issued a buy rating and a $17.00 price target on the stock.

Other equities analysts have also issued reports about the company. Wells Fargo & Company reduced their target price on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Wednesday, December 11th. Citigroup restated a “neutral” rating and issued a $7.50 price objective (down previously from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Pulmonx has an average rating of “Moderate Buy” and a consensus target price of $13.36.

Pulmonx Trading Down 3.5 %

NASDAQ LUNG opened at $7.22 on Monday. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $287.33 million, a P/E ratio of -5.01 and a beta of 0.50. The business has a fifty day simple moving average of $6.97 and a 200 day simple moving average of $6.94. Pulmonx has a 12 month low of $5.46 and a 12 month high of $10.01.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The company had revenue of $23.77 million during the quarter, compared to the consensus estimate of $22.29 million. On average, analysts predict that Pulmonx will post -1.55 EPS for the current fiscal year.

Insider Transactions at Pulmonx

In related news, insider Geoffrey Beran Rose sold 5,779 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.13, for a total transaction of $41,204.27. Following the sale, the insider now directly owns 285,278 shares in the company, valued at approximately $2,034,032.14. The trade was a 1.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel David Aaron Lehman sold 22,355 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.65, for a total value of $171,015.75. Following the completion of the transaction, the general counsel now owns 175,496 shares of the company’s stock, valued at approximately $1,342,544.40. This represents a 11.30 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 127,986 shares of company stock worth $986,673. 5.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Pulmonx

Hedge funds and other institutional investors have recently modified their holdings of the stock. Deerfield Management Company L.P. Series C purchased a new position in Pulmonx during the fourth quarter valued at approximately $10,421,000. FMR LLC grew its position in shares of Pulmonx by 11.2% during the 3rd quarter. FMR LLC now owns 5,872,882 shares of the company’s stock valued at $48,686,000 after purchasing an additional 591,859 shares in the last quarter. PFM Health Sciences LP bought a new position in shares of Pulmonx in the third quarter worth $3,058,000. Altium Capital Management LLC raised its position in shares of Pulmonx by 63.0% in the fourth quarter. Altium Capital Management LLC now owns 815,000 shares of the company’s stock worth $5,534,000 after buying an additional 315,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC bought a new stake in Pulmonx during the third quarter valued at $1,711,000. 91.04% of the stock is currently owned by institutional investors.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.